Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ 40,659	$ (84,906)	$ (42,925)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	13,132	14,141	3,062
Loss (gain) on disposal of property and equipment	0	(4,952)	14
Loss (gain) on sale of marketable securities	779	0	0
Unrealized exchange gain	(8,969)	(6,252)	0
Grants recognized in research and development expenses and operating income	(1,498)	(589)	(676)
Remeasurement of related party acquisition-related contingent consideration	30,957	60,503	28,135
Remeasurement of related party financing-related contingent consideration	4,883	3,319	1,990
Imputed interest on long-term debt	0	0	712
Change in deferred tax and income tax deferred charge	1,420	(2,806)	(11,320)
Stock-based compensation expense	7,741	2,690	2,029
Increase (decrease) in cash from:
Accounts receivable	(8,108)	3,426	(511)
Inventories	2,547	(3,112)	(2,186)
Prepaid expenses and other current assets	(610)	(2,330)	315
Research and development tax credit receivable	2,975	13,210	665
Accounts payable & other current liabilities	(3,887)	8,090	800
Deferred revenue	3,815	(55)	(14)
Accrued expenses	(1,617)	(265)	1,211
Other long-term assets and liabilities	74	(10,730)	(1,977)
Net cash provided by (used in) operating activities	84,293	(10,618)	(20,676)
Cash flows from investing activities:
Purchases of property and equipment	(1,629)	(1,728)	(1,029)
Proceeds from disposal of property and equipment	0	13,242	1,007
Proceeds from sales of marketable securities	20,490	13,678	7,152
Purchase of marketable securities	(50,591)	(68,275)	(1,085)
Net cash provided by (used in) investing activities	(31,730)	(43,083)	6,045
Cash flows from financing activities:
Reimbursment of loans	(4,911)	(34,186)	0
Reimbursment of conditional R&D grants	(747)	(355)	(475)
Proceeds from loans or conditional R&D grants	0	0	19,333
Principal payments on capital lease obligations	0	(161)	(77)
Earn-out payments for related party acquisition-related contingent consideration	(24,526)	(1,357)	(907)
Royalty payments for related party financing-related contingent consideration	(3,371)	(206)	0
Excess tax benefit from stock-based compensation	2,814	0	0
Cash proceeds from issuance of ordinary shares and warrants	6,990	132,260	400
Net cash provided by (used in) financing activities	(23,751)	95,995	18,274
Effect of exchange rate changes on cash and cash equivalents	(3,508)	(9,170)	251
Net increase in cash and cash equivalents	25,304	33,124	3,894
Cash and cash equivalents at January 1	39,760	6,636	2,742
Cash and cash equivalents at December 31	65,064	39,760	6,636
Supplemental disclosures of cash flow information:
Income tax paid	42,121	403	153
Interest paid	4,738	4,431	1,701
Supplemental schedule of non-cash investing and financing activities:
Income tax paid Grants recognized in research and development expenses and operating income	$ (1,498)	$ 0	$ 0